{"title":"Identification and Characterization of SNP Mutation in Genes related to Non-small cell lung cancer","authors":"Neelambika B. Hiremath, Dayananda P","doi":"10.2174/1574362415999200819202218","DOIUrl":null,"url":null,"abstract":"\n\n The advent of Next Generation Sequencing (NGS) has created a high throughput\nplatform, to identify disease traits and phenotypic characteristics using RNASeq Sequencing analysis in humans. Non-small\ncell lung cancer (NSCLC), a lethal disease accounts for 85 percent of most lung cancers with very small window ofsurvival\nrate. The decision of tumour image bio marker impression can be improved by gene profile. Hence there is a need to\ncharacterise the variants in the disease manifestation.\n\n\n\nTo understand the SNP’s in the major genes responsible for NSCLC, RNASeq data of patients aged above 50\nyears, were downloaded from SRA database. The quality matrix analysis is mapped to Genome reference consortium human\nbuild 38 (GRCh38) to call the variants and identify SNP’s with the tuxedo protocol.\n\n\n\n The SNP’s and the patterns of variants were analysed to see the comparison between healthy individual and NSCLC\npatients, and in between patients of different age. Oncogenes commonly associated with the NSCLC like KRAS, EGFR,\nALK, BRAF and HER2 were mainly analysed to see the SNP’s and their characterisations with respect to the functional\nchange was done.\n\n\n\n The SNP’s with the greater quality scores belonging to the above said genes were identified which gives us a\nbaseline to understand the NSCLC at the Genomic level. Further fold change of these genes to the frequency of variant can\nbe mapped to understand the NSCLC at a greater depth.\n","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Signal Transduction Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574362415999200819202218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
The advent of Next Generation Sequencing (NGS) has created a high throughput
platform, to identify disease traits and phenotypic characteristics using RNASeq Sequencing analysis in humans. Non-small
cell lung cancer (NSCLC), a lethal disease accounts for 85 percent of most lung cancers with very small window ofsurvival
rate. The decision of tumour image bio marker impression can be improved by gene profile. Hence there is a need to
characterise the variants in the disease manifestation.
To understand the SNP’s in the major genes responsible for NSCLC, RNASeq data of patients aged above 50
years, were downloaded from SRA database. The quality matrix analysis is mapped to Genome reference consortium human
build 38 (GRCh38) to call the variants and identify SNP’s with the tuxedo protocol.
The SNP’s and the patterns of variants were analysed to see the comparison between healthy individual and NSCLC
patients, and in between patients of different age. Oncogenes commonly associated with the NSCLC like KRAS, EGFR,
ALK, BRAF and HER2 were mainly analysed to see the SNP’s and their characterisations with respect to the functional
change was done.
The SNP’s with the greater quality scores belonging to the above said genes were identified which gives us a
baseline to understand the NSCLC at the Genomic level. Further fold change of these genes to the frequency of variant can
be mapped to understand the NSCLC at a greater depth.
期刊介绍:
In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.
The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.